从疾病预防到生育治疗:基于安全性与有效性重新思考线粒体置换在卵子相关不孕中的应用
该文讨论 maternal spindle transfer(MST)与 pronuclear transfer(PNT)在预防线粒体病和治疗卵子相关不孕两类应用中的监管与伦理问题。作者指出临床数据稀缺,认为禁止 MST/PNT 用于不孕缺乏正当性,也不应因其证据不足而仅先用于不孕,并提出分阶段评估可治疗病因、开展临床前研究与临床试验的路径。
要点
- MST/PNT 在英国和澳大利亚被允许用于预防 mtDNA 疾病,但不允许用于卵子相关不孕。
- MST/PNT 用于不孕的临床证据稀缺,其有效性与潜在风险尚不明确。
- 作者建议先识别 MST/PNT 可治疗的卵子相关不孕病因,再行临床前研究与临床试验。
核心结论
- 禁止 MST/PNT 用于不孕缺乏正当性。
- 不应因证据不足而仅先将 MST/PNT 用于不孕。
- 应通过分阶段研究路径评估 MST/PNT 对卵子相关不孕的适用性。
研究设计与样本
- 本文为论述性文章,讨论 MST/PNT 在预防 mtDNA 疾病与治疗卵子相关不孕两类应用中的监管、伦理与证据问题。
主要发现
- MST/PNT 用于不孕的临床数据稀缺。
- 英国和澳大利亚不允许 MST/PNT 用于卵子相关不孕,但允许其用于 mtDNA 疾病。
- 有提议基于风险降低先治疗卵子相关不孕再用于 mtDNA 疾病。
临床怎么用
- 应先识别 MST/PNT 可治疗的卵子相关不孕病因。
- 在临床前研究与临床试验结果积极后再考虑更广泛应用。
- 应透明发布定期试验结果并加强伦理反思与政策一致性。
局限性
- MST/PNT 用于不孕的有效性与潜在风险证据稀缺。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Maternal spindle transfer (MST) and pronuclear transfer (PNT) raise a number of important ethical and regulatory issues. These IVF procedures that transfer nuclear DNA to enucleated oocytes or zygotes aim to prevent transmitting mitochondrial disease by female carriers of mitochondrial DNA (mtDNA) mutations and enable them to have healthy genetically related children. MST/PNT might also prove effective in treating oocyte-related infertility, but are not permitted in the UK and Australia, unlike MST/PNT for mtDNA disorders. The paper discusses the regulation of MST/PNT for both applications in relation to their risks and efficacy, highlighting the scarcity of clinical data. Based on risk reduction, it has even been proposed to treat oocyte-related infertility first before moving to mtDNA disorders. We argue that a prohibition of MST/PNT for infertility is not justified, neither should it initially be applied only for infertility because of the little evidence yet available regarding its efficacy and potential risks. We propose a staged approach to identify MST/PNT-treatable causes of oocyte-related infertility first, followed by a preclinical study and clinical trial and, if positive, wider application. Importantly, we call for transparency in publishing regular trial results, deeper ethical reflection, and more consistent policies that consider comparable uncertainties in mtDNA disorders and oocyte-related infertility.
引用
- Pasturino F, De Wert GMWR, Herbrand C, et al. From disease prevention to fertility treatment: rethinking the use of mitochondrial donation for oocyte-related infertility in the light of safety and efficacy. Hum Reprod. 2026. PMID: 41821298. doi:10.1093/humrep/deag027
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。